AllTranz

About:

AllTranz, Inc., a pharmaceutical company, engages in the development of pharmaceutical products via dermal solutions.

Website: http://www.alltranz.com/

Top Investors: Commonwealth Seed Capital, Bluegrass Angels, Kentucky Seed Capital Fund

Description:

AllTranz is a specialty pharmaceutical company developing a unique set of dermal delivery products utilizing two proprietary technology platforms consisting of prodrug development and microneedle formulations. AllTranz will be a leader in the development of innovative drug design strategies delivered via unique dermal product solutions to treat neurological and a variety of other disorders. The broad range of offerings includes solutions for pain modulation, appetite stimulation, smoking cessation, substitution treatment for opiate addiction, as well as alcohol abuse, and abuse deterrent formulations for opiates. AllTranz will utilize its unique dermal drug delivery technology to develop its own products for broad market appeal, as well as partner with pharmaceutical companies seeking to leverage the AllTranz technology platform to improve delivery of existing drugs to form new chemical entities thereby extending patent franchises.

Total Funding Amount:

$860000

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Lexington, Kentucky, United States

Founded Date:

2004-01-01

Founders:

Number of Employees:

1-10

Last Funding Date:

2007-07-16

IPO Status:

Private

Industries:

© 2025 bioDAO.ai